Related Experiment Video
Updated: Jun 20, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming
Richard Marcotte1, Lixin Zhou, Harold Kim
1Goodman Cancer Center, Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Abstract:
Previous studies have demonstrated that c-Src tyrosine kinase interacts specifically with ErbB2, but not with other members of the epidermal growth factor receptor (EGFR) family. To identify the site of interaction, we recently used a chimeric EGFR/ErbB2 receptor approach to show that c-Src requires the kinase region of ErbB2 for binding. Here, we demonstrate that retention of a conserved amino acid motif surrounding tyrosine 877 (referred to here as EGFR(YHAD)) is sufficient to confer binding to c-Src. Surprisingly the association of c-Src was not dependent on its SH2 or SH3 domain or on the phosphorylation or kinase activity of the receptor. We further show that the chimeric EGFRs that contain the Y877 motif are transforming in vitro and in vivo following ligand stimulation. Transformation was also partially dependent on sustained activation of Stat3. Finally, we demonstrate that EGFRs with mutations in the catalytic domain, originally identified in lung cancer and conferring increased sensitivity to gefitinib and erlotinib, two EGFR kinase inhibitors, gained the capacity to bind c-Src. Moreover, transformation by these EGFR mutants was inhibited by Src inhibitors regardless of their sensitivities to gefitinib and erlotinib. These observations have important implications for understanding the molecular basis for resistance to EGFR inhibitors and implicate c-Src as a critical signaling molecule in EGFR mutant-induced transformation.
Insights
The epidermal growth factor receptor (EGFR) Y877 motif binds c-Src tyrosine kinase, driving cancer cell transformation. This interaction is crucial for understanding EGFR inhibitor resistance and implicates c-Src in mutant EGFR-driven cancers.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncology
Background:
- c-Src tyrosine kinase specifically interacts with ErbB2, a member of the epidermal growth factor receptor (EGFR) family.
- Previous research identified the kinase region of ErbB2 as necessary for c-Src binding using a chimeric receptor approach.
Purpose of the Study:
- To pinpoint the specific amino acid motif within EGFR responsible for c-Src binding.
- To investigate the functional consequences of c-Src binding to EGFR, including cellular transformation.
- To explore the role of c-Src in EGFR inhibitor resistance, particularly in lung cancer.
Main Methods:
- Utilized chimeric EGFR/ErbB2 receptors to map the c-Src interaction site.
- Introduced specific mutations, including the Y877 motif (EGFR(YHAD)), into EGFR constructs.
- Assessed in vitro and in vivo transformation assays following ligand stimulation.
- Investigated the role of Stat3 activation and Src inhibitors in EGFR-mediated transformation.
- Examined EGFR mutants found in lung cancer for their capacity to bind c-Src and their sensitivity to kinase inhibitors.
Main Results:
- The conserved amino acid motif surrounding tyrosine 877 (EGFR(YHAD)) is sufficient for c-Src binding, independent of Src domains or kinase activity.
- Chimeric EGFRs with the Y877 motif induced transformation in vitro and in vivo, partially dependent on Stat3 activation.
- EGFR mutants conferring sensitivity to gefitinib and erlotinib gained the ability to bind c-Src.
- Src inhibitors blocked transformation by these EGFR mutants, irrespective of their sensitivity to EGFR inhibitors.
Conclusions:
- The EGFR Y877 motif is a key determinant for c-Src interaction and subsequent cellular transformation.
- c-Src plays a critical role in mediating transformation induced by EGFR mutants, including those resistant to EGFR inhibitors.
- Targeting c-Src may offer a therapeutic strategy for cancers driven by EGFR mutants, especially in cases of acquired resistance to EGFR-targeted therapies.
Related Concept Videos
TGF - β Signaling Pathway
MAPK Signaling Cascades
Mitogens and the Cell Cycle
Receptor Tyrosine Kinases
The Ras Gene
Ras is a superfamily...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...

